Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Vertex Pharmaceuticals Incorporated (VRTX) P/S ratio

As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/S ratio of 10.6×. Over the past ten years it has ranged from 6.4× (October 2021) to 54.4× (March 2015); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 11.5× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 9.7× 2.49%
FY2024 9.4× (12.16%)
FY2023 10.7× 30.82%
FY2022 8.2× 9.78%
FY2021 7.5× (24.49%)
FY2020 9.9× (26.72%)
FY2019 13.5× (2.35%)
FY2018 13.8× (9.57%)
FY2017 15.3× 42.04%
FY2016 10.8× (63.40%)

Quarterly

Period P/S ratio Change
Jun 2026 10.0× 7.81%
Mar 2026 9.3× (3.86%)
Dec 2025 9.7× 13.12%
Sep 2025 8.5× (14.68%)
42 more quarters

Against its own ten years

Low 6.4× High 54.4×
Ten-year median 11.9×
Current reading's percentile 40

P/S ratio against peers

Company P/S ratio
REGN Regeneron Pharmaceuticals, Inc. compare 5.2×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.6×
ALNY Alnylam Pharmaceuticals, Inc. compare 7.1×
RPRX Royalty Pharma PLC compare 10.2×
VRTX Vertex Pharmaceuticals Incorporated 10.6×
ARGX argenex SE compare 11.2×
INSM Insmed, Inc. compare 22.5×
MRNA Moderna, Inc. compare 35.5×
RVMD Revolution Medicines, Inc. compare 1,606×
Biotechnology industry median 11.5×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on VRTX